
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.

Dr. Donna Culton describes the heterogeneous presentation and diagnosis of bullous pemphigoid at EADV 2025
This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Learn from Drs. Buchheit and Wagenmann as they discuss key patient traits that predict disease recurrence in CRSwNP.
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

Dr Henrik Watz discusses the two main COPD phenotypes: emphysema-predominant and bronchitis-predominant, detectable via clinical assessment and CT imaging.

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.